X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
lomitapide (100) 100
humans (55) 55
index medicus (52) 52
mipomersen (48) 48
homozygous familial hypercholesterolemia (40) 40
hypercholesterolemia (40) 40
triglyceride transfer protein (38) 38
familial hypercholesterolemia (31) 31
cholesterol (30) 30
anticholesteremic agents - therapeutic use (29) 29
hyperlipoproteinemia type ii - drug therapy (28) 28
benzimidazoles - therapeutic use (27) 27
statins (27) 27
pharmacology & pharmacy (26) 26
hyperlipoproteinemia type ii - genetics (24) 24
peripheral vascular disease (24) 24
coronary-heart-disease (23) 23
cardiac & cardiovascular systems (22) 22
double-blind (21) 21
homozygote (21) 21
ezetimibe (20) 20
female (20) 20
low density lipoproteins (20) 20
male (20) 20
apolipoprotein-b (19) 19
atherosclerosis (19) 19
cholesterol, ldl - blood (19) 19
adult (18) 18
hyperlipoproteinemia type ii - blood (18) 18
safety (18) 18
genetic aspects (17) 17
treatment outcome (17) 17
efficacy (16) 16
cardiovascular (14) 14
drug therapy (14) 14
homozygous familial hypercholesterolaemia (14) 14
lipoprotein apheresis (14) 14
pcsk9 inhibitors (14) 14
anticholesteremic agents (13) 13
benzimidazoles - adverse effects (13) 13
carrier proteins - antagonists & inhibitors (13) 13
lipids (13) 13
middle aged (13) 13
oligonucleotides - therapeutic use (13) 13
placebo-controlled trial (13) 13
anticholesteremic agents - adverse effects (12) 12
care and treatment (12) 12
density-lipoprotein cholesterol (12) 12
guidance (12) 12
ldl-apheresis (12) 12
mutation (12) 12
association expert panel (11) 11
carrier proteins - metabolism (11) 11
diagnosis (11) 11
hyperlipoproteinemia type ii - therapy (11) 11
inhibition (11) 11
monoclonal-antibody (11) 11
open-label (11) 11
risk factors (11) 11
triglycerides (11) 11
biomarkers - blood (10) 10
hyperlipoproteinemia type ii - diagnosis (10) 10
low-density-lipoprotein (10) 10
management (10) 10
phenotype (10) 10
young adult (10) 10
apheresis (9) 9
genetic predisposition to disease (9) 9
ldl (9) 9
ldl apheresis (9) 9
ldl-c (9) 9
microsomal triglyceride transfer protein (9) 9
animals (8) 8
b synthesis inhibitor (8) 8
benzimidazoles - pharmacology (8) 8
hypolipidemic agents - therapeutic use (8) 8
ldl cholesterol (8) 8
lipoproteins (8) 8
low density lipoprotein (8) 8
low-density lipoprotein cholesterol (8) 8
pcsk9 (8) 8
subtilisin/kexin type 9 (8) 8
alirocumab (7) 7
anticholesteremic agents - pharmacology (7) 7
biochemistry & molecular biology (7) 7
blood component removal - methods (7) 7
cardiology (7) 7
cardiovascular disease (7) 7
health aspects (7) 7
receptors, ldl - genetics (7) 7
abetalipoproteinemia (6) 6
article (6) 6
b synthesis inhibition (6) 6
benzimidazoles - administration & dosage (6) 6
cardiovascular diseases - prevention & control (6) 6
cardiovascular risk (6) 6
heterozygous familial hypercholesterolemia (6) 6
ldl-cholesterol (6) 6
medicine & public health (6) 6
mtp inhibitor (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Atherosclerosis and Thrombosis, ISSN 1340-3478, 2017
Aim: There is an unmet need in Japan for more optimal lipid-lowering therapy (LLT) for patients with homozygous familial hypercholesterolemia (HoFH) who... 
Lomitapide | Hypercholesterolemia | LDL-C | Homozygous familial hypercholesterolemia
Journal Article
Journal of Atherosclerosis and Thrombosis, ISSN 1340-3478, 2018
Aim: Lomitapide is an oral inhibitor of the microsomal triglyceride transfer protein used to treat homozygous familial hypercholesterolemia (HoFH); patients... 
Lomitapide | Diet therapy | Homozygous familial hypercholesterolemia | Low-fat diet
Journal Article
European Heart Journal, ISSN 0195-668X, 2014, Volume 35, Issue 32, pp. 2146 - 2157
Journal Article
Journal of Atherosclerosis and Thrombosis, ISSN 1340-3478, 2015
Aims: Lomitapide is a licensed treatment for patients with homozygous familial hypercholesterolaemia in the USA, the EU, Canada, and Mexico. This study was... 
Pharmacodynamics | Lomitapide | Familial hypercholesterolaemia | Pharmacokinetics | Japanese
Journal Article
Atherosclerosis, ISSN 0021-9150, 2015, Volume 240, Issue 2, pp. 408 - 414
Journal Article
Journal of Atherosclerosis and Thrombosis, ISSN 1340-3478, 2016
Homozygous familial hypercholesterolemia (HoFH) is a rare genetic disorder, which leads to premature cardiovascular diseases. Microsomal triglyceride transport... 
MTP gene | Microsomal transfer protein | Lomitapide | Homozygous familial hypercholesterolemia
Journal Article
Journal of Clinical Lipidology, ISSN 1933-2874, 05/2019, Volume 13, Issue 3, pp. 397 - 401
We report for the first time the efficiency and safety of a 49-month compassionate use of the microsomal transfer protein inhibitor lomitapide in a child with... 
Microsomal transfer protein | Lomitapide | Aortic valve | Homozygous familial hypercholesterolemia | TRANSFER PROTEIN INHIBITOR | ATHEROSCLEROSIS | PHARMACOLOGY & PHARMACY | OPEN-LABEL
Journal Article
Deutsche Medizinische Wochenschrift, ISSN 0012-0472, 06/2016, Volume 141, Issue 12, pp. 878 - 881
Journal Article
Journal of Atherosclerosis and Thrombosis, ISSN 1340-3478, 2018, Volume 26, Issue 4, pp. 368 - 377
Aim: Lomitapide is an approved lipid-lowering agent indicated as adjunct to low-fat diet and standard lipid-lowering therapies (LLTs) including lipoprotein... 
Lomitapide | LDL-C | Lipid-lowering therapy | Homozygous familial hypercholesterolemia | TRIGLYCERIDE TRANSFER PROTEIN | PANEL | MANAGEMENT | PERIPHERAL VASCULAR DISEASE | INHIBITOR | Original
Journal Article
Current pharmaceutical design, ISSN 1381-6128, 2018, Volume 24, Issue 31, pp. 3616 - 3621
Background: Familial Hypercholesterolemia (FH) is an autosomal-dominant genetic disease, associated with premature atherosclerotic Cardiovascular Disease... 
LDL apheresis | PCSK9 inhibitors | ezetimibe | LDL-C | lomitapide | Homozygous familial hypercholesterolemia | statins | liver transplantation | mipomersen | TRIGLYCERIDE TRANSFER PROTEIN | LDL-APHERESIS | YOUNG-ADULTS | LIVER-TRANSPLANTATION | MANAGEMENT | INHIBITION | PHARMACOLOGY & PHARMACY | LIPOPROTEINS | CORONARY-ARTERY-DISEASE | CARDIOVASCULAR RISK | EXPERT PANEL
Journal Article
Journal of Atherosclerosis and Thrombosis, ISSN 1340-3478, 2019, Volume 26, Issue 1, pp. 72 - 83
Aim: Lomitapide is an oral inhibitor of the microsomal triglyceride transfer protein used to treat homozygous familial hypercholesterolemia (HoFH); patients... 
Lomitapide | Diet therapy | Homozygous familial hypercholesterolemia | Low-fat diet | VITAMIN-E | TOCOPHEROL | EFFICACY | SAFETY | CLINICIAN | GUIDANCE | ACID-COMPOSITION | MEN | PERIPHERAL VASCULAR DISEASE | INSIGHTS | Original
Journal Article
Journal Article